Christoph S. Lengauer
Founder bij Thrive Earlier Detection Corp.
Profiel
Christoph S.
Lengauer was the founder of Celsius Therapeutics, Inc. (founded in 2018) where he held the title of Chief Scientific Officer from 2019 to 2020, and Thrive Earlier Detection Corp.
(founded in 2019) where he previously held the title of Chief Innovation Officer & Director.
He is currently a Director at Presage Biosciences, Inc. (since 2015), MOMA Therapeutics, Inc., and IDRx, Inc. He previously held positions at Novartis Institutes for Biomedical Research, Inc. (2005-2008) as Executive Director & Senior Unit Head-Oncology, The Sidney Kimmel Comprehensive Cancer Center (1997-2005) as Associate Professor-Oncology, Sanofi SA (2008-2012) as Vice President, and Blueprint Medicines Corp.
(2012-2016) as Chief Scientific Officer & Chief Drug Hunter.
He was also a Venture Partner at Third Rock Ventures LLC (2016-2018), and an Independent Director at Relay Therapeutics, Inc. He served as an Independent Non-Executive Director at HOOKIPA Pharma, Inc. from 2018 to 2022.
He was also the Coaching Director at Baltimore Bays Soccer Club.
Dr. Lengauer holds an MBA from The Johns Hopkins University, a graduate degree from Universität Salzburg, and a doctorate from Ruprecht-Karls-Universität Heidelberg.
Actieve functies van Christoph S. Lengauer
Bedrijven | Functie | Begin |
---|---|---|
Presage Biosciences, Inc.
Presage Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Presage Biosciences, Inc. engages in development of novel drugs for treatment of cancers. It offers CIVO arrayed microinjection platform that allows for simultaneous assessment of multiple drugs or drug combinations directly in a single solid tumor while still in a patient’s body to assess efficacy, resistance, and drug synergies in the tumor’s native microenvironment. The company was founded by James M. Olson and Thane Kreiner in 2008 and is headquartered in Seattle, WA. | Director/Board Member | 24-11-2015 |
Thrive Earlier Detection Corp.
Thrive Earlier Detection Corp. Medical SpecialtiesHealth Technology Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA. | Founder | 01-01-2019 |
MOMA Therapeutics, Inc.
MOMA Therapeutics, Inc. BiotechnologyHealth Technology MOMA Therapeutics, Inc. operates as a biotechnology firm. The company was founded by Dorothee Kern, Eva Nogales, Johannes Walter, and Timur Yusufzai and is headquartered in Cambridge, MA. | Director/Board Member | - |
IDRx, Inc.
IDRx, Inc. Miscellaneous Commercial ServicesCommercial Services IDRx, Inc. is a clinical-stage biopharmaceutical company located in an undisclosed location. The American company is dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today's precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. The company's pipeline programs include small molecule tyrosine kinase inhibitors, and idrx-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). IDRx was founded in 2021 by Alexis A. Borisy, Nicholas B. Lydon, Ben Auspitz, George D. Demetri, and Robert M. Forrester. Ben Auspitz has been the CEO since incorporation. | Director/Board Member | - |
Eerdere bekende functies van Christoph S. Lengauer
Bedrijven | Functie | Einde |
---|---|---|
HOOKIPA PHARMA INC. | Director/Board Member | 30-06-2022 |
Celsius Therapeutics, Inc.
Celsius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Celsius Therapeutics, Inc. translates single-cell genomic insights into precision therapeutics for autoimmune diseases and cancer. The company was founded by Jeffrey A. Bluestone, Vijay K. Kuchroo, Christoph S. Lengauer, Aviv Regev and Ramnik Xavier in 2018 and is headquartered in Boston, MA. | Founder | 01-04-2020 |
BLUEPRINT MEDICINES CORPORATION | Chief Tech/Sci/R&D Officer | 21-11-2016 |
Sanofi SA | Corporate Officer/Principal | 01-01-2012 |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Director/Board Member | 01-05-2008 |
Opleiding van Christoph S. Lengauer
The Johns Hopkins University | Masters Business Admin |
Universität Salzburg | Graduate Degree |
Ruprecht-Karls-Universität Heidelberg | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
BLUEPRINT MEDICINES CORPORATION | Health Technology |
RELAY THERAPEUTICS, INC. | Health Technology |
HOOKIPA PHARMA INC. | Health Technology |
Bedrijven in privébezit | 10 |
---|---|
Presage Biosciences, Inc.
Presage Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Presage Biosciences, Inc. engages in development of novel drugs for treatment of cancers. It offers CIVO arrayed microinjection platform that allows for simultaneous assessment of multiple drugs or drug combinations directly in a single solid tumor while still in a patient’s body to assess efficacy, resistance, and drug synergies in the tumor’s native microenvironment. The company was founded by James M. Olson and Thane Kreiner in 2008 and is headquartered in Seattle, WA. | Health Technology |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Commercial Services |
The Sidney Kimmel Comprehensive Cancer Center
The Sidney Kimmel Comprehensive Cancer Center Hospital/Nursing ManagementHealth Services The Sidney Kimmel Comprehensive Cancer Center offers immune-based treatments for cancer. The company was founded by Sidney Kimmel in 1973 and is headquartered in Baltimore, MD. | Health Services |
Sanofi SA | Health Technology |
Celsius Therapeutics, Inc.
Celsius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Celsius Therapeutics, Inc. translates single-cell genomic insights into precision therapeutics for autoimmune diseases and cancer. The company was founded by Jeffrey A. Bluestone, Vijay K. Kuchroo, Christoph S. Lengauer, Aviv Regev and Ramnik Xavier in 2018 and is headquartered in Boston, MA. | Health Technology |
Thrive Earlier Detection Corp.
Thrive Earlier Detection Corp. Medical SpecialtiesHealth Technology Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA. | Health Technology |
MOMA Therapeutics, Inc.
MOMA Therapeutics, Inc. BiotechnologyHealth Technology MOMA Therapeutics, Inc. operates as a biotechnology firm. The company was founded by Dorothee Kern, Eva Nogales, Johannes Walter, and Timur Yusufzai and is headquartered in Cambridge, MA. | Health Technology |
Baltimore Bays Soccer Club | |
IDRx, Inc.
IDRx, Inc. Miscellaneous Commercial ServicesCommercial Services IDRx, Inc. is a clinical-stage biopharmaceutical company located in an undisclosed location. The American company is dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today's precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. The company's pipeline programs include small molecule tyrosine kinase inhibitors, and idrx-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). IDRx was founded in 2021 by Alexis A. Borisy, Nicholas B. Lydon, Ben Auspitz, George D. Demetri, and Robert M. Forrester. Ben Auspitz has been the CEO since incorporation. | Commercial Services |
Third Rock Ventures LLC
Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Finance |